AstraZeneca Licenses Dizal’s Zegfrovy for Up to $1.5B

Company AstraZeneca / Dizal Pharmaceutical Event Type Global licensing agreement Modality Oral, irreversible small-molecule EGFR inhibitor Asset Zegfrovy (sunvozertinib) Target EGFR exon 20 insertion mutations Disease Area Non-small cell lung cancer (NSCLC) Summary AstraZeneca has entered an exclusive global license agreement with China-based Dizal Pharmaceutical…